Clinical trials
Fibrosis clinical trials
Below are recruiting fibrosis clinical trials, each written for real people, not researchers. We’re tracking 414 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05766774Recruiting
Diet study for adults with cystic fibrosis and high sugar intake
This trial studies whether changing eating habits—especially added sugar intake—affects health in adults with cystic fibrosis. It may help by testing a diet approach aimed at better outcomes related to metabolism and overall health.
Atlanta, GeorgiaAges 18 years+ - NCT03437486Recruiting
Family study for inherited lung scarring causes
This study looks at what causes familial (inherited) pulmonary fibrosis by studying relatives who are not yet diagnosed with the lung disease. You may help researchers understand risk and early changes in the lungs within families.
Nashville, TennesseeAges 40–75 - NCT07284459RecruitingPhase 2
Testing PIPE 791 for idiopathic pulmonary fibrosis
This trial tests an investigational drug called PIPE 791 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug slows lung function decline, and you may continue your current IPF medicine.
Mar del Plata, Buenos AiresAges 40 years+ - NCT04160715Recruiting
Registry for people with idiopathic pulmonary fibrosis in Korea
This study is a registry that collects health information from people diagnosed with idiopathic pulmonary fibrosis (IPF). It may help researchers better understand IPF and how it changes over time, even if it doesn’t involve a new medication.
Seongnam-siAges 30–100 - NCT04026360Recruiting
Study early lung, virus, and gut changes in children with cystic fibrosis
This study looks at how a child’s early lung function, viral infections, and gut (microbiome) changes affect cystic fibrosis over time. It may help doctors understand what predicts how lung disease develops, which could improve future care.
BernAges birth–18 years - NCT05200429Recruiting
Study of long-term effects of CFTR modulator medicines in CF
This observational study follows people with cystic fibrosis (CF) to understand the long-term impact of CFTR modulator medicines. It may help researchers see how these treatments work over time in real life.
Vancouver, British ColumbiaAges Any age - NCT03839992Recruiting
Checks for hidden small airways blockage in cystic fibrosis
This trial looks for early, “hidden” breathing test abnormalities in people with cystic fibrosis who have normal routine lung test results. It may help researchers find blockage in smaller airways before it shows up on standard tests.
Lakewood, CaliforniaAges 5–40 - NCT02270476Recruiting
Study of how cystic fibrosis lung disease changes over time
This observational study follows children newly diagnosed with cystic fibrosis to understand how their lung disease develops. It may help doctors better predict disease course and choose the right timing for care.
Heidelberg, Baden-WurttembergAges Any age - NCT07868419RecruitingPhase 3
Nalbuphine tablets for chronic cough in pulmonary fibrosis
This trial tests an extended-release tablet called nalbuphine to reduce chronic coughing in people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring and often leads to a persistent cough. If you have IPF and have been coughing for at least 8 weeks, this study may help manage that symptom.
Wilmington, DelawareAges 40 years+ - NCT02965326Recruiting
Testing blood and swab markers to track new cystic fibrosis treatments
This study looks for simple signals (markers) that may show whether cystic fibrosis treatments are working. It includes people who take CF “modulator” medicines like ivacaftor, people who don’t, and people whose cystic fibrosis was ruled out after testing.
ParisAges Any age - NCT06308757Recruiting
Studying a very low calorie keto diet for fatty liver disease with scarring
This trial tests whether a very low calorie ketogenic diet (a strict low-carb, high-fat diet) can help people with non-alcoholic steatohepatitis (NASH) who have liver scarring. Participants will follow this diet for a year and have two liver biopsies to see if their liver health improves.
BolognaAges 18 years+ - NCT04137133Recruiting
Precision medicine study for young children with cystic fibrosis
This study enrolls newly diagnosed infants with cystic fibrosis to follow them during “precision medicine” care. It may help doctors better understand which treatments and monitoring work best, especially before certain infections develop.
RoscoffAges Up to 18 years - NCT04700358Recruiting
Study of antibacterial antibodies in adults with cystic fibrosis
This study looks at how your body’s antibacterial antibodies work in people with cystic fibrosis. It may help researchers understand immune responses in cystic fibrosis and guide better future treatments.
CologneAges 18 years+ - NCT06413459Recruiting
New markers for lung disease in cystic fibrosis
This study looks for biological markers (substances in your body) that can show if a lung infection with Mycobacterium abscessus is getting worse. It may help researchers develop better ways to track and treat the infection in people with cystic fibrosis.
Milan, MIAges 18 years+ - NCT06284577Recruiting
Quality of life and gut health in children with cystic fibrosis
This study looks at how a drug called ETI (a combination of three medicines) affects the quality of life and gut health of children with cystic fibrosis. If you or your child has the right type of CF and is between 2 and 18 years old, this trial may help us understand how treatment improves daily life and digestion.
OsloAges 2–18 - NCT07809867RecruitingPhase 4
How Trikafta moves through the body in cystic fibrosis
This study looks at how the medicine elexacaftor/tezacaftor/ivacaftor (often called Trikafta) works in the body in people with cystic fibrosis. It helps doctors understand the right dose and how the drug is processed, which may improve treatment for children and adults.
GenovaAges 6 years+ - NCT06509230Recruiting
Predicting serious liver scarring in hepatitis B patients
This study looks at better ways to predict significant liver fibrosis (scarring) in people with chronic hepatitis B or non-alcoholic fatty liver disease. It aims to help avoid invasive tests like liver biopsy.
Hangzhou, ZhejiangAges 18–60 - NCT05651724Recruiting
MASH screening study for people with diabetes or obesity
This study screens participants for MASH (a type of liver fat inflammation) using information about your health and risk factors. It may help you and your care team learn whether you could have MASH and need follow-up.
Brussels, Vlaams-brabantAges 18–75 - NCT06323876Recruiting
Using CT scans to personalize treatment for pulmonary fibrosis
This study uses detailed CT scans to find better ways to treat idiopathic pulmonary fibrosis (IPF). It may help doctors choose the right treatment for each person.
Charlottesville, VirginiaAges 40–101 - NCT07761377Recruiting
Using AI to spot lung scarring on CT scans
This study tests whether an AI tool can correctly find lung scarring (pulmonary fibrosis) on CT scans as well as doctors do. The results could lead to faster, more consistent detection of this condition.
TaichungAges 20 years+ - NCT07750535Recruiting
Liver fat and scarring in wheat-sensitive patients
This study looks at whether people with non-celiac wheat sensitivity or other digestive conditions have more fat in their liver or liver scarring. It aims to understand if wheat-related issues are linked to liver health.
Palermo, PalermoAges 18–65 - NCT07729787Recruiting
Autogenic drainage vs. chest percussion for kids with CF
This trial compares two breathing techniques to help clear mucus from the lungs of children with cystic fibrosis. It aims to see if one method (autogenic drainage) works better than another (mechanical percussion with a vest).
Multan Khurd, Punjab ProvinceAges 6–12 - NCT07723872Recruiting
Finger vs. earlobe oxygen test during a 6-minute walk
This study compares oxygen levels measured at the finger versus the earlobe during a 6-minute walk test for people with interstitial lung disease. It helps find the most accurate way to monitor your oxygen during exercise.
Granollers, SpainAges 18 years+ - NCT07720375RecruitingPhase 2
Study of galvokimig for non-cystic fibrosis bronchiectasis
This study tests a new medicine called galvokimig for adults with non-cystic fibrosis bronchiectasis, a condition where airways are damaged and cause chronic cough and sputum. The goal is to see if it reduces flare-ups and improves lung health.
Brandon, FloridaAges 18–80
Hear when a new Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for fibrosis?
- Yes. Clin2 currently lists 414 recruiting fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.